Targeted therapeutics in SLE: emerging strategies to modulate the interferon pathway. Issue 5 (13th May 2016)

• Record Type: Journal Article
• Authors: Oon, Shereen; Wilson, Nicholas J; Wicks, Ian
• Is Part Of: Clinical & translational immunology. Volume 5:Issue 5 (2016)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2016-05-13
• Subjects: Immunologic diseases -- Periodicals; Immunology -- Periodicals; Clinical medicine -- Periodicals; Immune System Diseases -- therapy; Immunotherapy; Immunologic Factors -- therapeutic use; Translational Medical Research; Molecular Targeted Therapy; Clinical medicine; Immunologic diseases; Immunology; Periodicals; Periodicals; Fulltext; Internet Resources; Periodicals; 616.079
• DOI: 10.1038/cti.2016.26
• Languages: English
• ISSNs: 2050-0068

Abstract

Abstract : Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease characterized by impaired immune tolerance, resulting in the generation of pathogenic autoantibodies and immune complexes. Although autoreactive B lymphocytes have been the first targets for biologic therapies in SLE, the importance of the innate immune system, and in particular, pathways involved in interferon (IFN) signaling, has emerged. There are now data supporting a central role for a plasmacytoid dendritic cell‐derived type I IFN pathway in SLE, with a number of biologic therapeutics and small‐molecule inhibitors undergoing clinical trials. Monoclonal antibodies targeting IFN‐α have completed phase II clinical trials, and an antibody against the type I IFN receptor is entering a phase III trial. However, other IFNs, such as IFN gamma, and the more recently discovered type III IFNs, are also emerging as targets in SLE; and blockade of upstream components of the IFN signaling pathway may enable inhibition of more than one IFN subtype. In this review, we discuss the current understanding of IFNs in SLE, focusing on emerging therapies.